8-K: BIO-key International Faces Nasdaq Delisting Risk Due to Stockholders' Equity Deficiency

BIO-key International has received a notice from Nasdaq regarding its failure to meet the minimum stockholders' equity requirement for continued listing.

Summary

• BIO-key International received a notice from Nasdaq on June 10, 2024, stating that the company does not meet the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market.
• This deficiency is based on the company's reported stockholders' equity in its Annual Report on Form 10-K for the year ended December 31, 2023.
• The company has 45 calendar days, until July 25, 2024, to submit a plan to Nasdaq to regain compliance.
• If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days for the company to demonstrate compliance.
• If the plan is not accepted, or if the company fails to regain compliance within the extension period, the company may request a hearing before a Nasdaq Hearings Panel.
• There is no guarantee that the company will be able to regain compliance with the listing rule.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The risk of delisting is a significant concern for investors.

Positives

• The company intends to submit a compliance plan to Nasdaq within the required timeframe.
• The company has the option to request a hearing before a Nasdaq Hearings Panel if its plan is not accepted or if it fails to regain compliance, which would stay any delisting action.

Negatives

• The company's stockholders' equity is below the required minimum of $2,500,000.
• There is no assurance that the company will be able to regain compliance with Nasdaq listing rules.
• The company faces the risk of potential delisting from the Nasdaq Capital Market.

Risks

• The company may not be able to prepare and submit a compliance plan in a timely manner.
• Nasdaq may not accept the company's compliance plan.
• The company may not be able to regain compliance within the given timeframe, even with an extension.
• The company's shares could be delisted from the Nasdaq Capital Market if compliance is not achieved.

Future Outlook

The company intends to submit a compliance plan to Nasdaq and may be granted an extension to regain compliance, but there is no guarantee of success.

Management Comments

• The company intends to timely submit a compliance plan to the Nasdaq Capital Market.

Industry Context

This announcement highlights the challenges faced by smaller companies in maintaining listing requirements, particularly in volatile market conditions. It is not uncommon for companies to receive delisting notices, and the outcome depends on their ability to demonstrate a viable path to compliance.

Comparison to Industry Standards

• Many small-cap companies on the Nasdaq Capital Market struggle to maintain the minimum stockholders' equity requirement, especially during periods of financial difficulty.
• Companies like BIO-key are often compared to other technology firms in the security and identity management space, where profitability and consistent revenue growth are key to maintaining investor confidence and meeting listing requirements.
• Other companies that have faced similar delisting notices include those in the biotech and emerging tech sectors, where high research and development costs can impact profitability and equity levels.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in share value.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• The company must submit a compliance plan to Nasdaq by July 25, 2024.
• Nasdaq will review the plan and decide whether to grant an extension.
• The company may need to request a hearing if its plan is not accepted or if it fails to regain compliance.

Key Dates

Keywords

delisting, Nasdaq, stockholders' equity, compliance, listing rule, BIO-key International, BKYI